Episode 4 - Trends in 2017: Power to Patients, Payers, Changes in Regulation and Lower R&D Productivity

What The Pharma

Content provided by whatthepharma. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by whatthepharma or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

7+ y ago 10:38

M4A•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on February 01, 2021 23:27 (3y ago). Last successful fetch was on November 27, 2018 01:34 (5+ y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

In this episode, I take a look at the Magic 8 Ball to determine the trends to watch out for in Pharma for 2017. Patient consumerism continues to increase while payers grow influence over which drugs to reimburse & how. Changes in regulations are expected across the board to allow novel therapies where the unspoken race to become the powerhouse for gene and cell therapy center continues around the globe. New insights are provided to whether current level of technology is viable in the area of gene and cell therapy as well as impact of biosimilars in the market. Last but not least, R&D productivity continues to wither as newer incremental jumps are not incorporated to make R&D in pharma more productive - regulation changes may help resolve some of these challenges.

11 episodes

#Science #Medicine #whatthepharma